Ruxolitinib
Overview
Ruxolitinib is a small molecule Janus kinase inhibitor used to treat myelofibrosis and polycythemia vera. It functions by inhibiting the JAK1 and JAK2 proteins, interfering with cytokine signaling involved in hematological malignancies.
API suppliers (5)
Suppliers of Ruxolitinib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 4 of 5 suppliers.
4 of 5 hold a GMP certificate on record in the EU or UK registers
- MSN Laboratories Private LimitedIndia3 active DMF GMP on record
- DR REDDYS LABORATORIES LTD2 active DMF GMP on record
- CHONGQING HUAPONT SHENGCHEM PHARMACEUTICAL CO LTDChina1 active DMF
- CHANGZHOU PHARMACEUTICAL FACTORYChina1 active DMF GMP on record
- Granules India LimitedIndia1 active DMF GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (11 approved US products), the latest listed US patent on Ruxolitinib expires 5 May 2041 and exclusivity 22 Mar 2029. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- propanoic acid
- Canonical SMILES
- CCC(=O)O
- InChIKey
- XBDQKXXYIPTUBI-UHFFFAOYSA-N
Therapeutic areas
Do you supply Ruxolitinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.